Adjuvant chemotherapy in stage III colon cancer: Guideline implementation, patterns of use and outcomes in daily practice in The Netherlands

Figures & data

Figure 1. Study profile. Number of patients registered by the NCR in 2005–2006.

Figure 2. Distribution of regimen use from the first quartile of 2005 to the first quartile of 2007, by treatment group.

Table I. Baseline characteristics of stage III colon cancer patients receiving chemotherapy in Dutch daily clinical practice.

	Regimens without oxaliplatin		Oxaliplatin regimens
	5FUL/LV	Capecitabine	FOLFOX	CAPOX
Baseline characteristics	N = 17	N = 93	N = 136	N = 145	p-values
Age - year
Median	71	73	61	62	< 0.0001
Range	41–80	46–85	30–78	22–82
Age group - no. (%)
< 70	7 (41.2)	31 (33.3)	118 (86.8)	123 (84.8)	< 0.0001
≥ 70	10 (58.8)	62 (66.7)	18 (13.2)	22 (15.2)
Comorbid conditions - no. (%)
0–1	12 (70.6)	71 (76.3)	115 (84.6)	134 (92.4)	0.001
2 ^+	5 (29.4)	22 (23.7)	21 (15.4)	11 (7.6)
Sex - no. (%)
male	9 (52.9)	47 (50.5)	72 (52.9)	81 (55.9)	0.528
female	8 (47.1)	46 (49.5)	64 (47.1)	64 (44.1)
Depth of invasion - no. (%)
T2–T3	15 (88.2)	82 (89.1)	116 (85.3)	123 (84.8)	0.313
T4	2 (11.8)	10 (10.9)	20 (14.7)	22 (15.2)
Unknown
Nodes involved - no. (%)
N1	11 (64.7)	62 (66.7)	84 (61.8)	85 (58.6)	0.255
N2	6 (35.3)	31 (33.3)	52 (38.2)	60 (41.4)
Histologic appearance - no. (%)
Well differentiated	11 (64.7)	75 (81.5)	111 (86.7)	125 (91.9)	0.007
poorly differentiated	6 (35.3)	17 (18.5)	17 (13.3)	11 (8.1)
Unknown		1	8	9
CEA level - no.
< 5 ng/ml (ULN)	10 (83.3)	69 (93.2)	94 (83.2)	105 (80.8)	0.028
≥ 5 ng/ml (ULN)	2 (16.7)	5 (6.8)	19 (16.8)	25 (19.2)
Unknown	5	19	23	15

CEA, carcinoembryonic antigen

ULN, upper limit of normal

Table II. Planned and actually delivered dose in Dutch daily clinical practice.

			FOLFOX		CAPOX
	5FUL/LV	Capecitabine	5FU/LV	Oxaliplatin	Capecitabine	Oxaliplatin
	N = 15	N = 89	N = 37		N = 65
Median no. of cycles received (planned no. of cycles)	**	8(8)	12(12)	12(12)	8(8)	7(8)
Dose planned according to guidelines in mg/m^2/wk	**	11666	1000/200	43	9333	43
Mean dose over all cycles given in mg/m^2/wk	**	9659	890/178	42	8049	42
Mean dose over all planned cycles in mg/m^2/wk	**	8250	800/160	36^*1	7052	30^*1
% of patients requiring modification (for dose reduction or interruption)	53%	57%	54%	59%^*2	50%	70%^*2
% of planned dose given	72%	83%	84%	84%^*3	79%	71%^*3

**Not reported because of diversity of dose schedules and low patient numbers

^*1p-value = 0.0213, ^*2 p-value = 0.2661, ^*3 p-value = 0.0896, Oxaliplatin in FOLFOX versus CAPOX

Figure 3. Kaplan-Meier curves of disease-free survival in the groups of oxaliplatin patients that did and did not meet the MOSAIC eligibility criteria.